{"id":23200,"date":"2023-04-18T10:09:40","date_gmt":"2023-04-18T08:09:40","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=23200"},"modified":"2023-04-18T10:21:14","modified_gmt":"2023-04-18T08:21:14","slug":"andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/","title":{"rendered":"Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics"},"content":{"rendered":"<p><strong>Andera Partners<\/strong>, a leading European private equity player, today announces the successful completion of a Series A extension financing, co-led with Earlybird Venture Capital, for Ariceum Therapeutics (Ariceum), a radiopharmaceutical specialist developing products for the diagnosis and treatment of certain hard-to-treat cancers. Ariceum raised an additional \u20ac\u00a022.75 million, following the \u20ac\u00a025 million Series A financing announced in June 2022. Existing investor Pureos Bioventures also participated in the round, now doubling its original investment in the Company. As part of the investment, Olivier Litzka, Partner at Andera Partners, and Christoph Massner, Principal at Earlybird, will join the Ariceum Board of Directors.<\/p>\n<p>Ariceum intends to use the proceeds from the financing to advance its clinical pipeline and to further build the Company focusing on its lead asset and proprietary peptide derivative, Satoreotide, as well as building a pipeline of further projects.<\/p>\n<p>Satoreotide is a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in many cancers, including certain neuroendocrine and other aggressive, hard-to-treat cancers with poor prognoses such as small cell lung cancer (SCLC). Ariceum aims to use satoreotide as a \u2018theranostic\u2019 for both the diagnosis and treatment of tumours expressing the SST2 receptor. Satoreotide is in early clinical development and, as of today, has been administered to more than 100 patients including more than 150 therapeutic administrations in different indications.<\/p>\n<p><strong>Manfred R\u00fcdiger, PhD, Chief Executive Officer of Ariceum Therapeutics<\/strong>, said: \u201c<em>As we continue to make promising progress at Ariceum, the new funds will allow us to advance our clinical pipeline of diagnosis, monitoring and precision treatments to improve the lives of those facing very challenging cancers. The additional investment is a strong endorsement of our targeted radiotherapy product and reflects the opportunity that radiopharmaceutical drugs offer in visualizing and treating cancer. We are very pleased to welcome both Andera Partners and Earlybird Venture Capital to our investment syndicate and would like to thank our existing investors for their continued support<\/em>.\u201d<\/p>\n<p><strong>Olivier Litzka, PhD, Partner of Andera Partners<\/strong>, remarked: \u201c<em>At Andera we have been following the radiopharmaceuticals space for some time, looking for an opportunity to support a compelling project. As a result, we are now very happy to be able to back the talented and experienced team of Ariceum with a first clinical project centered around a meaningful disease application in Small Cell Lung Cancer. It is great to support the company in its bold ambition to build a pipeline of radiopharma projects through deals and partnerships. We are also joining an already powerful board of experts and strong European VCs. Altogether, we believe these are solid grounds to build a leading biotech company in the radiopharmaceuticals field<\/em>.\u201d<\/p>\n<p><strong>Christoph Massner, PhD, Principal of Earlybird Venture Capital<\/strong>, commented: &#8220;<em>We are delighted to support Ariceum as it advances its proprietary clinical programs to address aggressive cancers with a poor prognosis. Earlybird is especially excited about Ariceum\u2019s ability to stratify patients for treatment via its theranostics approach. This will provide the best possible patient outcomes and attractive health economics. I look forward to working with Ariceum\u2019s experienced management team and strong investor base as it enters its next development stage.<\/em>\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Andera Partners, a leading European private equity player, today announces the successful completion of a Series A extension financing, co-led with Earlybird Venture Capital, for Ariceum Therapeutics (Ariceum), a radiopharmaceutical specialist developing products for the diagnosis and treatment of certain hard-to-treat cancers. Ariceum raised an additional \u20ac\u00a022.75 million, following the \u20ac\u00a025 million Series A financing&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-23200","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Andera Partners, a leading European private equity player, today announces the successful completion of a Series A extension financing, co-led with Earlybird Venture Capital, for Ariceum Therapeutics (Ariceum), a radiopharmaceutical specialist developing products for the diagnosis and treatment of certain hard-to-treat cancers. Ariceum raised an additional \u20ac\u00a022.75 million, following the \u20ac\u00a025 million Series A financing...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T08:09:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-18T08:21:14+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics\",\"datePublished\":\"2023-04-18T08:09:40+00:00\",\"dateModified\":\"2023-04-18T08:21:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/\"},\"wordCount\":534,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/\",\"name\":\"Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2023-04-18T08:09:40+00:00\",\"dateModified\":\"2023-04-18T08:21:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics - ANDERA PARTNERS","og_description":"Andera Partners, a leading European private equity player, today announces the successful completion of a Series A extension financing, co-led with Earlybird Venture Capital, for Ariceum Therapeutics (Ariceum), a radiopharmaceutical specialist developing products for the diagnosis and treatment of certain hard-to-treat cancers. Ariceum raised an additional \u20ac\u00a022.75 million, following the \u20ac\u00a025 million Series A financing...","og_url":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2023-04-18T08:09:40+00:00","article_modified_time":"2023-04-18T08:21:14+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics","datePublished":"2023-04-18T08:09:40+00:00","dateModified":"2023-04-18T08:21:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/"},"wordCount":534,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/","url":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/","name":"Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2023-04-18T08:09:40+00:00","dateModified":"2023-04-18T08:21:14+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-series-a-extension-round-of-e-47-75-million-for-radiopharmaceutical-company-ariceum-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Andera Partners co-leads a Series A extension round of \u20ac 47.75 million for radiopharmaceutical company Ariceum Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/23200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=23200"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/23200\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=23200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=23200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}